Davita Inc vs Halliburton Company — how do they compare? Davita Inc trades at $178.99 (market cap $11.29B), while Halliburton Company trades at $32.57 (market cap $27.14B). The key difference: Halliburton Company is far larger — about 2.4× Davita Inc's market cap, and Halliburton Company pays a 2.09% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Halliburton Company for 89 Days on average.
| DVA | HAL | |
|---|---|---|
Market Cap | $11.29B | $27.14B |
Volume | 582,204 | 11,258,156 |
Sector | Health | Energy |
52-Week High | $240.96 | $42.98 |
52-Week Low | $103.87 | $21.82 |
Typical Hold Time | 113 Days | 89 Days |
Enterprise Value | $24.01B | $33.29B |
Dividend Yield | — | 2.09% |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
Halliburton (HAL) trades at $32.57, up 2.58% today, with a bearish technical signal despite recent earnings beats. The company shows solid profitability with a 7.16% net income margin and 14.89% ROE, though revenue dipped slightly in 2025. Recent news highlights expansion in Venezuela and a new deepwater contract in Cyprus, signaling growth initiatives. Analyst consensus is strongly bullish with a $43.11 price target, but technical indicators and recent CFO stock sales introduce caution.
The outlook for HAL is mixed; strong analyst support and strategic contracts offer upside, but technical weakness and exposure to oil price volatility pose risks. Investors should weigh the company's solid fundamentals and growth projects against market sentiment and industry cyclicality for balanced decision-making.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →